Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board
December 17 2021 - 11:54AM
InvestorsHub NewsWire
Protocol Title: The Effect
of CBD Gum on Nausea and Vomiting During
Pregnancy
New York, NY -- December 17, 2021 -- InvestorsHub
NewsWire -- Tauriga Sciences, Inc. (OTCQB:
TAUG) (“Tauriga” or the “Company”), a New York based
diversified Life Sciences Company, today announced that it has
formally submitted its Clinical Study Protocol (“Protocol”) to the
Institutional Review Board (“IRB”). The Company’s
Protocol Title: “The Effect of CBD Gum on Nausea and Vomiting
During
Pregnancy”.
The purpose of this Clinical Study is: to examine
the Effects of Different Cannabidiol Doses on
Reducing the Frequency and Severity of Nausea in Otherwise Healthy
Pregnant Women with Excessive First Trimester Emesis and the
Diagnosis of Hyperemesis
Gravidarum.
Hyperemesis Gravidarum is also known as: Morning
Sickness
On December 16, 2021 the IRB acknowledged receipt
of the Company’s above-referenced Study Protocol (CIRBI Link:
Pro00059685).
The IRB will begin Administrative Review of the
Protocol Submission, and notify the Company if there are any
clarifications
required.
The Company’s proposed Cannabidiol delivery system
(via: sublingual absorption / oral mucosa) utilizes its proprietary
Cannabidiol infused chewing gum platform. This focuses on
Sublingual Delivery, which refers to the pharmacological route of
administration by which substances diffuse into the blood through
tissues under the tongue. The Company expects to develop
“mission critical” versions of its proprietary chewing gum,
incorporating varying concentrations of CBD (potentially combined
with other
substances).
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8
THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc
Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused
Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused
Tauri-Gum™ Flavor: Golden Raspberry). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is
its ongoing Pharmaceutical Development initiative. This
relates to the development of a proposed Pharmaceutical grade
version of Tauri-Gum™, for nausea regulation (specifically designed
for the following indication: Patients Subjected to Ongoing
Chemotherapy Treatment). On March 22, 2021, the Company announced
that it had Converted its U.S. Provisional Patent Application
(filed on March 17, 2020) into a U.S. Non-Provisional Patent
Application. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. On December 18, 2020 the Company
disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company's clinical development
efforts.
The Company is headquartered in Wappingers Falls,
New York. In addition, the Company operates two full
time E-Commerce fulfillment centers: one located in Montgomery,
Texas and the other in Brooklyn, New
York.
DISCLAIMER -- Forward-Looking
Statements
This press release contains certain
“forward-looking statements” as defined by the Private Securities
Litigation Reform Act of 1995 which represent management’s beliefs
and assumptions concerning future events. These forward-looking
statements are often indicated by using words such as “may,”
“will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as
well as the attainment of certain corporate goals and milestones.
Forward-looking statements are based on present circumstances and
on management’s present beliefs with respect to events that have
not occurred, that may not occur, or that may occur with different
consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed in
forward looking statements due to known and unknown risks and
uncertainties, such as are not guarantees of general economic and
business conditions, the ability to successfully develop and market
products, consumer and business consumption habits, the ability to
consummate successful acquisition and licensing transactions,
fluctuations in exchange rates, and other factors over which
Tauriga has little or no control. Many of these risks and
uncertainties are discussed in greater detail in the “Risk Factors”
section of Tauriga’s Form 10-K and other periodic filings made from
time to time with the Securities and Exchange Commission. Such
forward-looking statements are made only as of the date of this
release, and Tauriga assumes no obligation to update
forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these
forward-looking
statements.
Contact:
Tauriga Sciences,
Inc.
4
Nancy Court, Suite 4
Wappingers Falls, NY
12590
Chief Executive
Officer
Mr. Seth M.
Shaw
Email: sshaw@tauriga.com
cell # (917) 796
9926
Company Instagram:
@taurigum
Personal
Instagram: @sethsms47
Twitter:
@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com